NYSE - Nasdaq Real Time Price USD

GSK plc (GSK)

Compare
34.15 +0.19 (+0.56%)
At close: November 25 at 4:00 PM EST
34.24 +0.09 (+0.26%)
Pre-Market: 8:46 AM EST
Loading Chart for GSK
DELL
  • Previous Close 33.96
  • Open 34.05
  • Bid 34.06 x 900
  • Ask --
  • Day's Range 34.02 - 34.25
  • 52 Week Range 32.83 - 45.93
  • Volume 4,147,179
  • Avg. Volume 5,768,176
  • Market Cap (intraday) 69.675B
  • Beta (5Y Monthly) 0.33
  • PE Ratio (TTM) 22.32
  • EPS (TTM) 1.53
  • Earnings Date Feb 5, 2025
  • Forward Dividend & Yield 1.56 (4.58%)
  • Ex-Dividend Date Nov 15, 2024
  • 1y Target Est 45.95

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.

www.gsk.com

70,212

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GSK

View More

Performance Overview: GSK

Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GSK
4.21%
FTSE 100
7.05%

1-Year Return

GSK
0.87%
FTSE 100
10.55%

3-Year Return

GSK
7.27%
FTSE 100
13.24%

5-Year Return

GSK
3.62%
FTSE 100
11.92%

Compare To: GSK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GSK

View More

Valuation Measures

Annual
As of 11/25/2024
  • Market Cap

    69.19B

  • Enterprise Value

    85.36B

  • Trailing P/E

    22.34

  • Forward P/E

    7.49

  • PEG Ratio (5yr expected)

    0.73

  • Price/Sales (ttm)

    1.79

  • Price/Book (mrq)

    3.95

  • Enterprise Value/Revenue

    2.17

  • Enterprise Value/EBITDA

    10.11

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.02%

  • Return on Assets (ttm)

    7.24%

  • Return on Equity (ttm)

    21.85%

  • Revenue (ttm)

    31.31B

  • Net Income Avi to Common (ttm)

    2.51B

  • Diluted EPS (ttm)

    1.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.21B

  • Total Debt/Equity (mrq)

    119.37%

  • Levered Free Cash Flow (ttm)

    6.04B

Research Analysis: GSK

View More

Company Insights: GSK

Research Reports: GSK

View More

People Also Watch